US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SILO PHARMA INC.

0.6604

-0.0339-4.88%

Post-market: 0.6590-0.0014-0.21%19:18 EDT

Volume:292.96K

Turnover:194.23K

Market Cap:4.76M

PE:-0.58

High:0.6900

Open:0.6713

Low:0.6500

Close:0.6943

Loading ...

Overview Company News Filings

Silo Pharma Inc. Completes Dosing in Safety Study of PTSD Drug SPC-15, Awaits Bioanalytical Results

Silo Pharma expects preclinical study data on SPC-15 in Q3

Silo Pharma Inc. Awaits Pre-Clinical Data for SPC-15, Plans IND Submission for PTSD Drug in 2025 with Potential Phase 1 Trials by 2026

Silo Pharma Inc. Faces Nasdaq Non-Compliance Over Minimum Bid Price Rule

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

MT Newswires Live

Silo Pharma enters into letter of intent to form 50:50 joint venture with Hoth

BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics

Silo Pharma Inc. Announces USPTO Notice of Allowance for Biomarker Patent on Novel PTSD Therapeutic SPC-15

Silo Pharma Inc. Board Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset for Long-Term Value Optimization

Eric Weisblum, CEO of Silo Pharma Inc., Reports Acquisition of Common Shares

Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15

MT Newswires Live

Silo Pharma, Resyca partner for intranasal drug-device study of SPC-15

Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission

BRIEF-Silo Pharma Announces Closing Of $2 Million Public Offering

Silo Pharma Inc. Completes $2 Million Public Offering of Common Stock and Warrants

Silo Pharma Announces $2 Million Public Offering of Shares and Warrants

Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15

Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials

BRIEF-Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study

BRIEF-Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer’S Drug

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SILO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SILO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SILO\",,,,,undefined,":{"symbol":"SILO","market":"US","secType":"STK","nameCN":"SILO PHARMA INC.","latestPrice":0.6604,"timestamp":1753387200000,"preClose":0.6943,"halted":0,"volume":292964,"hourTrading":{"tag":"盘后","latestPrice":0.659,"preClose":0.6604,"latestTime":"19:18 EDT","volume":18717,"amount":12066.8226,"timestamp":1753399131668},"delay":0,"floatShares":6523300,"shares":7207792,"eps":-1.131679,"marketStatus":"Closed","change":-0.0339,"latestTime":"07-24 16:00:00 EDT","open":0.6713,"high":0.69,"low":0.65,"amount":194225.43489160002,"amplitude":0.057612,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.131679,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753430400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.6943,"preHourTrading":{"tag":"盘前","latestPrice":0.6875,"preClose":0.6943,"latestTime":"09:27 EDT","volume":19673,"amount":13106.565733,"timestamp":1753363626110},"postHourTrading":{"tag":"盘后","latestPrice":0.659,"preClose":0.6604,"latestTime":"19:18 EDT","volume":18717,"amount":12066.8226,"timestamp":1753399131668},"volumeRatio":0.900891},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SILO\",,,,,undefined,":{"symbol":"SILO","floatShares":6523300,"roa":"-47.89%","roe":"-99.38%","lyrEps":-1.193591,"volumeRatio":0.900891,"shares":7207792,"dividePrice":0,"high":0.69,"amplitude":0.057612,"preClose":0.6943,"low":0.65,"week52Low":0.4101,"pbRate":"1.19","psRate":"66.02","week52High":3.3699,"institutionHeld":0,"latestPrice":0.6604,"eps":-1.131679,"divideRate":0,"volume":292964,"delay":0,"ttmEps":-1.131679,"open":0.6713,"prevYearClose":0.89,"prevWeekClose":0.6255,"prevMonthClose":0.63,"prevQuarterClose":0.63,"fiveDayClose":0.632,"twentyDayClose":0.643,"sixtyDayClose":0.8401},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SILO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551123808","title":"Silo Pharma Inc. Completes Dosing in Safety Study of PTSD Drug SPC-15, Awaits Bioanalytical Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2551123808","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551123808?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:45","pubTimestamp":1752669917,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc.  has announced the completion of dosing in a safety study for its PTSD drug candidate, SPC-15. This study was conducted at the request of the U.S. Food and Drug Administration  and involved a 7-day safety and toxicology assessment in a large animal model. The company anticipates receiving the bioanalytical and safety/toxicology results within 60 days. Silo Pharma is also progressing with two additional preclinical studies: an IND-enabling GLP-compliant toxicology and toxicokinetic animal study, and a device study focused on SPC-15's formulation-specific microchip-based nasal spray system. The company plans to pursue the FDA's 505 regulatory pathway to potentially expedite the clinical approval process for SPC-15. Results from these studies are expected to be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL8XTQLy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","BK4585","BK4112","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD","SILO","BK4202","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2549321455","title":"Silo Pharma expects preclinical study data on SPC-15 in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2549321455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549321455?lang=en_us&edition=fundamental","pubTime":"2025-07-07 20:30","pubTimestamp":1751891415,"startTime":"0","endTime":"0","summary":"Silo Pharma (SILO) expects to receive data from the additional preclinical studies of its lead asset SPC-15 within the next 30 to 90 days. SPC-15 i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silo-pharma-expects-preclinical-study-data-on-spc-15-in-q3-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silo-pharma-expects-preclinical-study-data-on-spc-15-in-q3-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4202","SILO","SPC"],"gpt_icon":0},{"id":"2549534223","title":"Silo Pharma Inc. Awaits Pre-Clinical Data for SPC-15, Plans IND Submission for PTSD Drug in 2025 with Potential Phase 1 Trials by 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2549534223","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549534223?lang=en_us&edition=fundamental","pubTime":"2025-07-07 20:15","pubTimestamp":1751890522,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc. Awaits Pre-Clinical Data for SPC-15, Plans IND Submission for PTSD Drug in 2025 with Potential Phase 1 Trials by 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on July 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDL2qF8d6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4139","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","BK4585","BK4202","LU2095319765.USD","NDAQ","LU2210150020.SGD","BK4588","SILO","LU2210149790.SGD"],"gpt_icon":0},{"id":"2548747387","title":"Silo Pharma Inc. Faces Nasdaq Non-Compliance Over Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2548747387","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548747387?lang=en_us&edition=fundamental","pubTime":"2025-07-04 04:46","pubTimestamp":1751575577,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc. has announced that it has received a notification from The Nasdaq Stock Market indicating non-compliance with the minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550. The rule requires listed securities to maintain a minimum bid price of $1.00 per share over 30 consecutive business days. This notification, dated June 27, 2025, follows a period from May 14 to June 26, 2025, during which the company's stock price did not meet this threshold. Although the notification does not immediately affect the stock's trading on The Nasdaq Capital Market, Silo Pharma has until December 24, 2025, to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. The company is exploring options, including a reverse stock split, to address this issue. If compliance is not achieved within the initial 180-day period, a further extension may be possible, subject to meeting additional criteria.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL2TG0BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","SILO"],"gpt_icon":0},{"id":"2546924491","title":"Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2546924491","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546924491?lang=en_us&edition=fundamental","pubTime":"2025-06-25 23:34","pubTimestamp":1750865672,"startTime":"0","endTime":"0","summary":"Silo Pharma  entered a nonbinding letter of intent with Hoth Therapeutics  to form a 50-50 joint venture aimed at developing and commercialize treatments for obesity and metabolic diseases.The initiative will build on Hoth's technology, which is exclusively licensed from the US Department of Veterans Affairs and co-developed with Emory University, Silo Pharma said Wednesday in a statement.Silo Pharma shares eased 0.1% in recent trading Wednesday, and Hoth Therapeutics fell 4.1%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4202","HOTH","SILO","BK4185","BK4139","JYNT","BK4007"],"gpt_icon":0},{"id":"2546482802","title":"Silo Pharma enters into letter of intent to form 50:50 joint venture with Hoth","url":"https://stock-news.laohu8.com/highlight/detail?id=2546482802","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546482802?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:51","pubTimestamp":1750855867,"startTime":"0","endTime":"0","summary":"Silo Pharma (SILO) announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silo-pharma-enters-into-letter-of-intent-to-form-5050-joint-venture-with-hoth-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silo-pharma-enters-into-letter-of-intent-to-form-5050-joint-venture-with-hoth-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4202","SILO"],"gpt_icon":0},{"id":"2546106142","title":"BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2546106142","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546106142?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:32","pubTimestamp":1750854774,"startTime":"0","endTime":"0","summary":"BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth TherapeuticsJune 25 (Reuters) - Hoth Therapeutics Inc HOTH.O:SILO PHARMA: FORMATION OF STRATEGIC JOINT VENTURE WITH HOTH THERAPEUTICSSI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS075:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HOTH","SILO","BK4007","BK4202"],"gpt_icon":0},{"id":"2542821085","title":"Silo Pharma Inc. Announces USPTO Notice of Allowance for Biomarker Patent on Novel PTSD Therapeutic SPC-15","url":"https://stock-news.laohu8.com/highlight/detail?id=2542821085","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542821085?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:00","pubTimestamp":1749646821,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc. has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/954,858, titled \"Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.\" This patent, licensed from Columbia University, will strengthen the intellectual property protection for Silo's lead asset, SPC-15, an intranasal treatment for post-traumatic stress disorder . The patent is expected to be issued as U.S. Patent No. 12,329,726 on June 17, 2025. According to Eric Weisblum, CEO of Silo, this development enhances protection for the key technology behind their novel PTSD prophylactic, which is being prepared for Phase 1 clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDLHw07b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","BK4585","IE00BGHQF748.EUR","SILO","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4202","BK4112"],"gpt_icon":0},{"id":"2541734650","title":"Silo Pharma Inc. Board Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset for Long-Term Value Optimization","url":"https://stock-news.laohu8.com/highlight/detail?id=2541734650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541734650?lang=en_us&edition=fundamental","pubTime":"2025-06-05 21:15","pubTimestamp":1749129309,"startTime":"0","endTime":"0","summary":"Silo Pharma, Inc. , a developmental stage biopharmaceutical company, announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. This strategic decision aims to diversify the company's assets by incorporating a digital store of value, potentially offering significant upside. CEO Eric Weisblum explained that the move is intended to safeguard against inflation and enhance long-term shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on June 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL2h1pw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4139","BK4585","NDAQ","BK4202","SILO","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2539240921","title":"Eric Weisblum, CEO of Silo Pharma Inc., Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2539240921","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539240921?lang=en_us&edition=fundamental","pubTime":"2025-05-29 04:31","pubTimestamp":1748464283,"startTime":"0","endTime":"0","summary":"Eric Weisblum, Chief Executive Officer and Director of Silo Pharma Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL8lhhN7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eric Weisblum, CEO of Silo Pharma Inc., Reports Acquisition of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","SILO"],"gpt_icon":0},{"id":"2537351299","title":"Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15","url":"https://stock-news.laohu8.com/highlight/detail?id=2537351299","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537351299?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:20","pubTimestamp":1747833605,"startTime":"0","endTime":"0","summary":"Silo Pharma  said Wednesday that it has signed a service agreement with medical technology firm Resyca for a drug-device study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder, or PTSD.Financial details were not disclosed.Silo said the study is expected to provide the necessary device data and documentation for SPC-15's investigational new drug application, which the company plans to submit to the US Food and Drug Administration this year.Silo is currently conducting two additional SPC-15 studies, it said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SILO","BK4139","SPC","BK4202"],"gpt_icon":0},{"id":"2537935383","title":"Silo Pharma, Resyca partner for intranasal drug-device study of SPC-15","url":"https://stock-news.laohu8.com/highlight/detail?id=2537935383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537935383?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:00","pubTimestamp":1747832425,"startTime":"0","endTime":"0","summary":"Silo Pharma (SILO) has entered into a service agreement with medical technology provider Resyca BV for a drug-device study of the formulation-speci...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silo-pharma-resyca-partner-for-intranasal-drug-device-study-of-spc-15?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silo-pharma-resyca-partner-for-intranasal-drug-device-study-of-spc-15?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4202","SPC","SILO"],"gpt_icon":0},{"id":"2537933163","title":"Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2537933163","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537933163?lang=en_us&edition=fundamental","pubTime":"2025-05-21 20:55","pubTimestamp":1747832112,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc. has announced a new clinical study in collaboration with Resyca BV, focusing on the drug-device combination for their lead asset, SPC-15. The study aims to collect the final device data and documentation necessary for an Investigational New Drug  submission to the U.S. Food and Drug Administration  later this year. SPC-15 is designed as an intranasal treatment for post-traumatic stress disorder  and utilizes a microchip-based nasal spray system to deliver molecules directly to the brain, bypassing the blood-brain barrier. This approach is intended to increase drug concentration and potentially enhance therapeutic outcomes. Currently, Silo Pharma is also conducting an IND-enabling GLP-compliant toxicology and toxicokinetics study, along with an FDA-requested 7-day safety and toxicology study in large animals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL7464vq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","SILO","IE00B3QW5Z07.USD","NDAQ","BK4202","LU2095319765.USD","BK4139","BK4588","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2536340263","title":"BRIEF-Silo Pharma Announces Closing Of $2 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2536340263","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536340263?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:15","pubTimestamp":1747426525,"startTime":"0","endTime":"0","summary":"BRIEF-Silo Pharma Announces Closing Of $2 Million Public OfferingMay 16 (Reuters) - Silo Pharma Inc SILO.O:SILO PHARMA ANNOUNCES CLOSING OF $2 MILLION PUBLIC OFFERINGSource text: ID:nGNX7k4ScbFurther company coverage: SILO.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nTUADPPTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","SILO"],"gpt_icon":0},{"id":"2536234025","title":"Silo Pharma Inc. Completes $2 Million Public Offering of Common Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2536234025","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536234025?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:15","pubTimestamp":1747426520,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc., a developmental stage biopharmaceutical company, has successfully closed a public offering, raising approximately $2 million. The offering involved 3,333,338 shares of common stock, along with series A-1 and series A-2 warrants, each allowing the purchase of up to 3,333,338 additional shares at an exercise price of $0.60 per share. The Series A-1 Warrants are exercisable immediately and expire in five years, while the Series A-2 Warrants also become exercisable immediately but expire in eighteen months. The funds raised will be used for general working capital. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDLb5K3qw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","LU2095319765.USD","LU2210149790.SGD","BK4202","SILO","IE00B3QW5Z07.USD","BK4139"],"gpt_icon":0},{"id":"2535470823","title":"Silo Pharma Announces $2 Million Public Offering of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2535470823","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535470823?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:15","pubTimestamp":1747314912,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc., a developmental stage biopharmaceutical company, has announced the pricing of a $2 million public offering. The offering includes 3,333,338 shares of common stock along with Series A-1 and Series A-2 warrants, each allowing the purchase of an additional 3,333,338 shares at $0.60 per share. The Series A-1 Warrants will expire five years from issuance, and the Series A-2 Warrants will expire eighteen months from issuance. H.C. Wainwright & Co. is serving as the exclusive placement agent for this offering. The company plans to use the proceeds for general working capital purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewsw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL4YwHlW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","BK4588","BK4139","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4202","LU2210150020.SGD","SILO","LU2095319765.USD","IE00B64PRP62.GBP","BK4585"],"gpt_icon":0},{"id":"2535007979","title":"Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007979","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007979?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:15","pubTimestamp":1747253712,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc. has announced a significant step in the development of its novel intranasal PTSD therapy, SPC-15. The biopharmaceutical company, focused on pioneering therapeutics and drug delivery systems, has partnered with Veloxity Labs, LLC for a bioanalytical study necessary for the investigational new drug -enabling process. This collaboration aims to support the ongoing GLP-compliant toxicology and toxicokinetics study of SPC-15. Silo Pharma plans to initiate the FDA IND process later in 2025, with hopes of progressing to a first-in-human Phase 1 clinical trial following approval. The CEO, Eric Weisblum, highlighted the importance of Veloxity Labs in providing fast and precise data crucial for advancing SPC-15 into clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL5jKkl6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","BK4588","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4139","LU2210149790.SGD","BK4202","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SILO","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2535213170","title":"Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2535213170","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535213170?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:40","pubTimestamp":1747226412,"startTime":"0","endTime":"0","summary":"Silo Pharma Inc. , a developmental stage biopharmaceutical company, has announced a significant step forward in the development of its PTSD drug, SPC-15. The company has initiated a 7-day safety and toxicology study at Frontage Laboratories, a global contract research organization. This study, requested by the FDA, aims to gather crucial data to support Silo's investigational new drug  application for SPC-15, an intranasal prophylactic treatment targeting the multi-billion-dollar PTSD market. The company remains on track to submit an FDA application this year, with plans to proceed to a first-in-human Phase 1 clinical trial upon approval. Silo has an exclusive global license from Columbia University for the development and commercialization of SPC-15.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL8FlPgQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK4202","IE00B3QW5Z07.USD","BK0028","300347","IE00BKPKM429.USD","BK0174","LU2210149790.SGD","BK4588","LU1820825898.SGD","IE00BGHQF748.EUR","BK0216","LU1146622755.USD","BK4112","BK4585","IE00B64PRP62.GBP","SILO","NDAQ","LU2095319765.USD","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2531031360","title":"BRIEF-Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031360","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031360?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:13","pubTimestamp":1746015191,"startTime":"0","endTime":"0","summary":"BRIEF-Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia StudyApril 30 (Reuters) - Silo Pharma Inc SILO.O:SILO PHARMA’S SP-26 KETAMINE IMPLANT MEETS ALL ENDPOINTS IN FIBROMYALGIA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA6W9G1K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","SILO","BK4139"],"gpt_icon":0},{"id":"2530894662","title":"BRIEF-Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer’S Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2530894662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530894662?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:57","pubTimestamp":1745848677,"startTime":"0","endTime":"0","summary":"BRIEF-Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer’S DrugApril 28 (Reuters) - Silo Pharma Inc SILO.O:SILO PHARMA EXPANDS INTELLECTUAL ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R60U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","SILO"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SILO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-09","symbol":"SILO","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2025-03-28","symbol":"SILO","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"post","actualEps":-0.41},{"market":"US","date":"2024-11-12","symbol":"SILO","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-08-13","symbol":"SILO","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2024-05-13","symbol":"SILO","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":-0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SILO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SILO\",market:\"US\",delay:true,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SILO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:true,algorithm:1,,,undefined,":{"brief":{"id":"SILO","date":"2025-07-23","current":-0.985436,"percent":0.713588,"low":-49.251422,"twenty":-6.86005,"median":-1.502713,"eighty":2.520635,"high":6.268511,"avg":-3.147388,"sd":6.949554,"marketCap":4555324},"quantilePoints":[{"date":"2020-07-24","current":-36.938566,"twenty":-47.831013,"median":-11.610032,"eighty":-8.383446,"marketCap":37429627},{"date":"2020-07-31","current":-40.550337,"twenty":-47.831013,"median":-11.610032,"eighty":-8.383446,"marketCap":41089413},{"date":"2020-08-07","current":-40.550337,"twenty":-47.831013,"median":-11.610032,"eighty":-8.383446,"marketCap":41089413},{"date":"2020-08-14","current":-22.589384,"twenty":-47.831013,"median":-11.610032,"eighty":-8.383446,"marketCap":51085170},{"date":"2020-08-21","current":-22.589384,"twenty":-47.831013,"median":-11.610032,"eighty":-8.383446,"marketCap":51085170},{"date":"2020-08-28","current":-22.589384,"twenty":-47.831013,"median":-11.610032,"eighty":-8.383446,"marketCap":51085170},{"date":"2020-09-04","current":-15.812569,"twenty":-47.831013,"median":-11.920554,"eighty":-8.383446,"marketCap":35759619},{"date":"2020-09-11","current":-15.812569,"twenty":-46.11557,"median":-11.920554,"eighty":-8.383446,"marketCap":35759619},{"date":"2020-09-18","current":-13.177141,"twenty":-44.971941,"median":-11.920554,"eighty":-8.383446,"marketCap":29799682},{"date":"2020-09-25","current":-13.177141,"twenty":-44.971941,"median":-11.920554,"eighty":-8.383446,"marketCap":29799682},{"date":"2020-10-02","current":-13.177141,"twenty":-44.971941,"median":-12.605588,"eighty":-8.383446,"marketCap":29799682},{"date":"2020-10-09","current":-15.05959,"twenty":-44.971941,"median":-13.177141,"eighty":-8.383446,"marketCap":34056780},{"date":"2020-10-16","current":-17.318528,"twenty":-44.598482,"median":-13.177141,"eighty":-8.383446,"marketCap":39165297},{"date":"2020-10-23","current":-15.812569,"twenty":-44.34951,"median":-13.177141,"eighty":-8.383446,"marketCap":35759619},{"date":"2020-10-30","current":-7.529795,"twenty":-44.34951,"median":-13.177141,"eighty":-8.383446,"marketCap":17028390},{"date":"2020-11-06","current":-13.59794,"twenty":-42.414259,"median":-13.177141,"eighty":-8.383446,"marketCap":35759619},{"date":"2020-11-13","current":-13.921701,"twenty":-41.124091,"median":-13.177141,"eighty":-8.383446,"marketCap":36611038},{"date":"2020-11-20","current":-11.250677,"twenty":-41.124091,"median":-12.988896,"eighty":-8.383446,"marketCap":29586827},{"date":"2020-11-27","current":-11.979138,"twenty":-41.124091,"median":-12.950419,"eighty":-8.383446,"marketCap":31502521},{"date":"2020-12-04","current":-13.921701,"twenty":-41.124091,"median":-12.969658,"eighty":-8.383446,"marketCap":36611038},{"date":"2020-12-11","current":-14.083581,"twenty":-41.124091,"median":-12.950419,"eighty":-8.383446,"marketCap":37036748},{"date":"2020-12-18","current":-15.540503,"twenty":-40.894589,"median":-13.177141,"eighty":-8.383446,"marketCap":40868136},{"date":"2020-12-24","current":-13.59794,"twenty":-40.550337,"median":-13.177141,"eighty":-8.395489,"marketCap":35759619},{"date":"2020-12-31","current":-13.740395,"twenty":-40.550337,"median":-13.177141,"eighty":-8.44366,"marketCap":36134243},{"date":"2021-01-08","current":-11.331617,"twenty":-40.550337,"median":-13.177141,"eighty":-8.44366,"marketCap":29799682},{"date":"2021-01-15","current":-11.331617,"twenty":-40.550337,"median":-13.177141,"eighty":-8.44366,"marketCap":29799682},{"date":"2021-01-22","current":-11.338092,"twenty":-40.550337,"median":-12.969658,"eighty":-8.44366,"marketCap":29816710},{"date":"2021-01-29","current":-11.299241,"twenty":-40.550337,"median":-12.626659,"eighty":-8.44366,"marketCap":29714540},{"date":"2021-02-05","current":-11.623001,"twenty":-40.550337,"median":-12.545718,"eighty":-8.44366,"marketCap":30565960},{"date":"2021-02-12","current":-13.279636,"twenty":-40.550337,"median":-12.464778,"eighty":-8.44366,"marketCap":34922549},{"date":"2021-02-19","current":-12.955743,"twenty":-40.550337,"median":-12.464778,"eighty":-8.44366,"marketCap":34070780},{"date":"2021-02-26","current":-10.040701,"twenty":-40.410776,"median":-12.305427,"eighty":-8.44366,"marketCap":26404854},{"date":"2021-03-05","current":-9.230967,"twenty":-40.317736,"median":-12.222279,"eighty":-8.44366,"marketCap":24275430},{"date":"2021-03-12","current":-9.959727,"twenty":-40.317736,"median":-12.120246,"eighty":-8.44366,"marketCap":26191912},{"date":"2021-03-19","current":-10.364594,"twenty":-40.317736,"median":-11.979138,"eighty":-8.44366,"marketCap":27256624},{"date":"2021-03-26","current":-9.52571,"twenty":-40.317736,"median":-11.920554,"eighty":-8.44366,"marketCap":25050540},{"date":"2021-04-01","current":-8.412491,"twenty":-40.317736,"median":-11.920554,"eighty":-8.44366,"marketCap":25553085},{"date":"2021-04-09","current":-8.412491,"twenty":-38.966068,"median":-11.920554,"eighty":-8.44366,"marketCap":25553085},{"date":"2021-04-16","current":-9.193088,"twenty":-36.938566,"median":-11.920554,"eighty":-8.44366,"marketCap":27924161},{"date":"2021-04-23","current":-9.745323,"twenty":-36.938566,"median":-11.660169,"eighty":-8.44366,"marketCap":29601585},{"date":"2021-04-30","current":-8.780536,"twenty":-36.938566,"median":-11.655378,"eighty":-8.44366,"marketCap":26671028},{"date":"2021-05-07","current":-8.283525,"twenty":-36.938566,"median":-11.65214,"eighty":-8.44366,"marketCap":25161347},{"date":"2021-05-14","current":-9.745323,"twenty":-36.938566,"median":-11.610032,"eighty":-8.412491,"marketCap":29601585},{"date":"2021-05-21","current":-6.887088,"twenty":-36.938566,"median":-11.610032,"eighty":-8.383446,"marketCap":25684308},{"date":"2021-05-28","current":-6.482277,"twenty":-36.938566,"median":-11.610032,"eighty":-8.383446,"marketCap":24174627},{"date":"2021-06-04","current":-6.614568,"twenty":-36.938566,"median":-11.610032,"eighty":-8.383446,"marketCap":24667987},{"date":"2021-06-11","current":-7.530024,"twenty":-36.938566,"median":-11.610032,"eighty":-8.383446,"marketCap":28082036},{"date":"2021-06-18","current":-6.74686,"twenty":-36.938566,"median":-11.610032,"eighty":-8.383446,"marketCap":25161347},{"date":"2021-06-25","current":-7.276025,"twenty":-36.938566,"median":-11.606813,"eighty":-8.383446,"marketCap":27134786},{"date":"2021-07-02","current":-6.088049,"twenty":-36.938566,"median":-11.543264,"eighty":-8.169095,"marketCap":22704415},{"date":"2021-07-09","current":-5.688529,"twenty":-36.938566,"median":-11.446551,"eighty":-8.132075,"marketCap":21214469},{"date":"2021-07-16","current":-5.291655,"twenty":-36.938566,"median":-11.336275,"eighty":-7.933662,"marketCap":19734390},{"date":"2021-07-23","current":-4.497906,"twenty":-36.938566,"median":-11.33271,"eighty":-7.930287,"marketCap":16774231},{"date":"2021-07-30","current":-4.167178,"twenty":-36.938566,"median":-11.331617,"eighty":-7.8797,"marketCap":15540832},{"date":"2021-08-06","current":-4.931822,"twenty":-36.938566,"median":-11.316925,"eighty":-7.772559,"marketCap":18392451},{"date":"2021-08-13","current":-6.194366,"twenty":-36.938566,"median":-11.316925,"eighty":-7.71145,"marketCap":17445200},{"date":"2021-08-20","current":-5.773934,"twenty":-36.938566,"median":-11.316925,"eighty":-7.530024,"marketCap":16261137},{"date":"2021-08-27","current":-5.780941,"twenty":-36.938566,"median":-11.316925,"eighty":-7.471816,"marketCap":16280871},{"date":"2021-09-03","current":-6.250424,"twenty":-36.938566,"median":-11.316925,"eighty":-7.408317,"marketCap":17603075},{"date":"2021-09-10","current":-5.938604,"twenty":-36.938566,"median":-11.316925,"eighty":-7.287866,"marketCap":16724895},{"date":"2021-09-17","current":-6.131302,"twenty":-36.938566,"median":-11.316925,"eighty":-7.030065,"marketCap":17267591},{"date":"2021-09-24","current":-6.481662,"twenty":-36.938566,"median":-11.316925,"eighty":-6.998719,"marketCap":18254310},{"date":"2021-10-01","current":-7.777994,"twenty":-36.938566,"median":-11.316925,"eighty":-6.998719,"marketCap":21905172},{"date":"2021-10-08","current":-7.991714,"twenty":-36.938566,"median":-11.294692,"eighty":-6.998719,"marketCap":22507071},{"date":"2021-10-15","current":-7.245447,"twenty":-36.938566,"median":-11.250677,"eighty":-6.998719,"marketCap":20405359},{"date":"2021-10-22","current":-6.485165,"twenty":-36.938566,"median":-11.169737,"eighty":-6.998719,"marketCap":18264177},{"date":"2021-10-29","current":-7.007202,"twenty":-36.938566,"median":-11.007857,"eighty":-6.998719,"marketCap":19734390},{"date":"2021-11-05","current":-6.989684,"twenty":-36.938566,"median":-10.863315,"eighty":-6.998719,"marketCap":19685054},{"date":"2021-11-12","current":4.813136,"twenty":-36.938566,"median":-10.781763,"eighty":-6.998719,"marketCap":20227749},{"date":"2021-11-19","current":4.578349,"twenty":-36.938566,"median":-10.765666,"eighty":-6.895555,"marketCap":19241030},{"date":"2021-11-26","current":4.425738,"twenty":-36.92924,"median":-10.765666,"eighty":-6.877034,"marketCap":18599662},{"date":"2021-12-03","current":3.873988,"twenty":-36.923022,"median":-10.684096,"eighty":-6.855846,"marketCap":16280871},{"date":"2021-12-10","current":3.648592,"twenty":-36.923022,"median":-10.684096,"eighty":-6.83062,"marketCap":15333621},{"date":"2021-12-17","current":3.744855,"twenty":-36.923022,"median":-10.417366,"eighty":-6.773318,"marketCap":15738176},{"date":"2021-12-23","current":3.169626,"twenty":-36.923022,"median":-10.364594,"eighty":-6.667326,"marketCap":13320713},{"date":"2021-12-31","current":3.345717,"twenty":-36.923022,"median":-10.273294,"eighty":-6.629914,"marketCap":14060752},{"date":"2022-01-07","current":3.39737,"twenty":-36.923022,"median":-10.104326,"eighty":-6.509381,"marketCap":14277831},{"date":"2022-01-14","current":3.709637,"twenty":-36.923022,"median":-10.104326,"eighty":-6.481662,"marketCap":15590168},{"date":"2022-01-21","current":3.756594,"twenty":-36.311797,"median":-10.104326,"eighty":-6.32658,"marketCap":15787512},{"date":"2022-01-28","current":3.991381,"twenty":-33.866898,"median":-10.104326,"eighty":-6.195768,"marketCap":16774231},{"date":"2022-02-04","current":4.460956,"twenty":-33.866898,"median":-10.072513,"eighty":-6.085932,"marketCap":18747670},{"date":"2022-02-11","current":4.554871,"twenty":-33.866898,"median":-10.040701,"eighty":-5.953713,"marketCap":19142358},{"date":"2022-02-18","current":3.780061,"twenty":-33.57661,"median":-9.745323,"eighty":-5.886049,"marketCap":15886135},{"date":"2022-02-25","current":4.460942,"twenty":-32.41546,"median":-9.734304,"eighty":-5.84751,"marketCap":18747613},{"date":"2022-03-04","current":4.233199,"twenty":-32.41546,"median":-9.713568,"eighty":-5.832266,"marketCap":17790498},{"date":"2022-03-11","current":3.521796,"twenty":-32.41546,"median":-9.66205,"eighty":-5.815977,"marketCap":14800747},{"date":"2022-03-18","current":3.406751,"twenty":-32.41546,"median":-9.66205,"eighty":-5.773934,"marketCap":14317256},{"date":"2022-03-25","current":3.573449,"twenty":-32.41546,"median":-9.66205,"eighty":-5.635612,"marketCap":15017825},{"date":"2022-04-01","current":5.560776,"twenty":-32.41546,"median":-9.66205,"eighty":-5.574758,"marketCap":21707829},{"date":"2022-04-08","current":6.268511,"twenty":-32.41546,"median":-9.66205,"eighty":-5.291655,"marketCap":24470643},{"date":"2022-04-14","current":5.310541,"twenty":-32.41546,"median":-9.66205,"eighty":-4.855357,"marketCap":20730976},{"date":"2022-04-22","current":4.4284,"twenty":-32.41546,"median":-9.66205,"eighty":-4.615857,"marketCap":17287325},{"date":"2022-04-29","current":3.98101,"twenty":-32.286443,"median":-9.622366,"eighty":-4.520661,"marketCap":15540832},{"date":"2022-05-06","current":4.233772,"twenty":-32.254189,"median":-9.596752,"eighty":-4.418002,"marketCap":16527551},{"date":"2022-05-13","current":3.409218,"twenty":-32.254189,"median":-9.596752,"eighty":-2.602183,"marketCap":14422258},{"date":"2022-05-20","current":3.406869,"twenty":-32.254189,"median":-9.596752,"eighty":3.174322,"marketCap":14412318},{"date":"2022-05-27","current":3.406869,"twenty":-32.254189,"median":-9.596752,"eighty":3.294533,"marketCap":14412318},{"date":"2022-06-03","current":3.406869,"twenty":-32.254189,"median":-9.540285,"eighty":3.400187,"marketCap":14412318},{"date":"2022-06-10","current":3.406869,"twenty":-32.254189,"median":-9.499117,"eighty":3.406869,"marketCap":14412318},{"date":"2022-06-17","current":3.059133,"twenty":-32.254189,"median":-9.499117,"eighty":3.406869,"marketCap":12941268},{"date":"2022-06-24","current":2.58781,"twenty":-32.254189,"median":-9.499117,"eighty":3.406869,"marketCap":10947398},{"date":"2022-07-01","current":2.584521,"twenty":-32.254189,"median":-9.499117,"eighty":3.406869,"marketCap":10933483},{"date":"2022-07-08","current":2.583346,"twenty":-32.254189,"median":-9.499117,"eighty":3.406845,"marketCap":10928513},{"date":"2022-07-15","current":3.049735,"twenty":-32.254189,"median":-9.499117,"eighty":3.406516,"marketCap":12901509},{"date":"2022-07-22","current":3.28939,"twenty":-32.254189,"median":-9.392914,"eighty":3.406516,"marketCap":13915342},{"date":"2022-07-29","current":3.251797,"twenty":-32.254189,"median":-9.320616,"eighty":3.405344,"marketCap":13756309},{"date":"2022-08-05","current":3.44955,"twenty":-32.254189,"median":-9.279879,"eighty":3.406845,"marketCap":13915342},{"date":"2022-08-12","current":3.264752,"twenty":-32.254189,"median":-9.230967,"eighty":3.406869,"marketCap":13169877},{"date":"2022-08-19","current":3.327583,"twenty":-32.254189,"median":-9.1175,"eighty":3.406869,"marketCap":13423335},{"date":"2022-08-26","current":3.397806,"twenty":-32.254189,"median":-9.1175,"eighty":3.406869,"marketCap":13706611},{"date":"2022-09-02","current":4.452383,"twenty":-32.254189,"median":-9.1175,"eighty":3.406869,"marketCap":17960730},{"date":"2022-09-09","current":4.893432,"twenty":-32.254189,"median":-9.1175,"eighty":3.406869,"marketCap":19739906},{"date":"2022-09-16","current":4.188739,"twenty":-32.254189,"median":-9.115932,"eighty":3.406869,"marketCap":16897201},{"date":"2022-09-23","current":3.529628,"twenty":-32.254189,"median":-9.074418,"eighty":3.406869,"marketCap":14238376},{"date":"2022-09-30","current":4.184954,"twenty":-32.254189,"median":-9.074418,"eighty":3.406869,"marketCap":16881934},{"date":"2022-10-07","current":4.426095,"twenty":-32.254189,"median":-9.074418,"eighty":3.409218,"marketCap":17854685},{"date":"2022-10-14","current":3.920478,"twenty":-32.254189,"median":-9.074418,"eighty":3.417518,"marketCap":15815046},{"date":"2022-10-21","current":3.337073,"twenty":-32.254189,"median":-9.074418,"eighty":3.429838,"marketCap":13461616},{"date":"2022-10-28","current":2.971473,"twenty":-32.254189,"median":-9.074418,"eighty":3.429838,"marketCap":11986800},{"date":"2022-11-04","current":2.917022,"twenty":-32.254189,"median":-9.074418,"eighty":3.422022,"marketCap":11767147},{"date":"2022-11-11","current":-3.27585,"twenty":-32.254189,"median":-9.074418,"eighty":3.417518,"marketCap":10923013},{"date":"2022-11-18","current":-3.341743,"twenty":-32.254189,"median":-9.074418,"eighty":3.416143,"marketCap":11142729},{"date":"2022-11-25","current":-3.426464,"twenty":-32.254189,"median":-9.074418,"eighty":3.410603,"marketCap":11425221},{"date":"2022-12-02","current":-3.30409,"twenty":-32.254189,"median":-9.074418,"eighty":3.409218,"marketCap":11017177},{"date":"2022-12-09","current":-3.435877,"twenty":-32.254189,"median":-8.907073,"eighty":3.409218,"marketCap":11456609},{"date":"2022-12-16","current":-2.456887,"twenty":-32.254189,"median":-8.834559,"eighty":3.409218,"marketCap":8192260},{"date":"2022-12-23","current":-2.824009,"twenty":-32.254189,"median":-8.772618,"eighty":3.409218,"marketCap":9416391},{"date":"2022-12-30","current":-3.162889,"twenty":-29.11202,"median":-8.622853,"eighty":3.409218,"marketCap":10546357},{"date":"2023-01-06","current":-2.654568,"twenty":-29.11202,"median":-8.622853,"eighty":3.406869,"marketCap":8851407},{"date":"2023-01-13","current":-2.663981,"twenty":-29.11202,"median":-8.622853,"eighty":3.406869,"marketCap":8882795},{"date":"2023-01-20","current":-2.447474,"twenty":-29.11202,"median":-8.622853,"eighty":3.406869,"marketCap":8160872},{"date":"2023-01-27","current":-2.412456,"twenty":-29.11202,"median":-8.622853,"eighty":3.400449,"marketCap":8044108},{"date":"2023-02-03","current":-2.546314,"twenty":-29.11202,"median":-8.622853,"eighty":3.333597,"marketCap":8490445},{"date":"2023-02-10","current":-2.343927,"twenty":-29.11202,"median":-8.622853,"eighty":3.313409,"marketCap":7815604},{"date":"2023-02-17","current":-2.551021,"twenty":-29.11202,"median":-8.622853,"eighty":3.284213,"marketCap":8506139},{"date":"2023-02-24","current":-2.118006,"twenty":-29.11202,"median":-8.622853,"eighty":3.258389,"marketCap":7062293},{"date":"2023-03-03","current":-2.230966,"twenty":-29.11202,"median":-8.622853,"eighty":3.220613,"marketCap":7438948},{"date":"2023-03-10","current":-2.05842,"twenty":-29.11202,"median":-8.622853,"eighty":3.203153,"marketCap":6863607},{"date":"2023-03-17","current":-1.788539,"twenty":-29.11202,"median":-8.622853,"eighty":3.169626,"marketCap":5963714},{"date":"2023-03-24","current":-1.664842,"twenty":-29.11202,"median":-8.622853,"eighty":3.109923,"marketCap":6507121},{"date":"2023-03-31","current":-1.697169,"twenty":-28.064631,"median":-8.622853,"eighty":3.062449,"marketCap":6633473},{"date":"2023-04-06","current":-1.818396,"twenty":-29.11202,"median":-8.622853,"eighty":3.028188,"marketCap":7107293},{"date":"2023-04-14","current":-1.922974,"twenty":-30.15941,"median":-8.623987,"eighty":2.91391,"marketCap":7516041},{"date":"2023-04-21","current":-1.74566,"twenty":-30.15941,"median":-8.623987,"eighty":2.672645,"marketCap":6823001},{"date":"2023-04-28","current":-1.810314,"twenty":-30.15941,"median":-8.623987,"eighty":2.584521,"marketCap":7075705},{"date":"2023-05-05","current":-1.757783,"twenty":-30.15941,"median":-8.623987,"eighty":2.535419,"marketCap":6870383},{"date":"2023-05-12","current":-1.761823,"twenty":-30.15941,"median":-8.623987,"eighty":2.380579,"marketCap":6886177},{"date":"2023-05-19","current":-1.552815,"twenty":-30.15941,"median":-8.613691,"eighty":0.794614,"marketCap":6538709},{"date":"2023-05-26","current":-1.560316,"twenty":-30.15941,"median":-8.610026,"eighty":0.794614,"marketCap":6570297},{"date":"2023-06-02","current":-1.62783,"twenty":-30.15941,"median":-8.509394,"eighty":0.794614,"marketCap":6854589},{"date":"2023-06-09","current":-1.665338,"twenty":-26.666627,"median":-8.509394,"eighty":0.794614,"marketCap":7012529},{"date":"2023-06-16","current":-1.635332,"twenty":-26.666627,"median":-8.444803,"eighty":0.794614,"marketCap":6886177},{"date":"2023-06-23","current":-1.567818,"twenty":-26.584576,"median":-8.44366,"eighty":1.57209,"marketCap":6601885},{"date":"2023-06-30","current":-1.567818,"twenty":-24.605518,"median":-8.44366,"eighty":2.349565,"marketCap":6601885},{"date":"2023-07-07","current":-1.515307,"twenty":-22.589384,"median":-8.44366,"eighty":2.349565,"marketCap":6380769},{"date":"2023-07-14","current":-1.53031,"twenty":-22.589384,"median":-8.44366,"eighty":2.349565,"marketCap":6443945},{"date":"2023-07-21","current":-1.515307,"twenty":-22.589384,"median":-8.44366,"eighty":2.349565,"marketCap":6380769},{"date":"2023-07-28","current":-1.447794,"twenty":-17.695018,"median":-8.396566,"eighty":2.349565,"marketCap":6096478},{"date":"2023-08-04","current":-1.620329,"twenty":-16.942038,"median":-8.383446,"eighty":2.349565,"marketCap":6823001},{"date":"2023-08-11","current":-1.53031,"twenty":-15.812569,"median":-8.383446,"eighty":2.349565,"marketCap":6443945},{"date":"2023-08-18","current":-1.299164,"twenty":-15.812569,"median":-8.383446,"eighty":2.349565,"marketCap":5931235},{"date":"2023-08-25","current":-1.29074,"twenty":-15.436079,"median":-8.383446,"eighty":2.349565,"marketCap":5892777},{"date":"2023-09-01","current":-1.285306,"twenty":-15.05959,"median":-8.212006,"eighty":2.349565,"marketCap":5867966},{"date":"2023-09-08","current":-1.365467,"twenty":-14.569222,"median":-8.130215,"eighty":2.349565,"marketCap":6233938},{"date":"2023-09-15","current":-1.317914,"twenty":-14.083581,"median":-7.962688,"eighty":2.349565,"marketCap":6016836},{"date":"2023-09-22","current":-1.24998,"twenty":-13.921701,"median":-7.930287,"eighty":2.349565,"marketCap":5706690},{"date":"2023-09-29","current":-1.14808,"twenty":-13.600564,"median":-7.8461,"eighty":2.349565,"marketCap":5241470},{"date":"2023-10-06","current":-1.086939,"twenty":-13.600564,"median":-7.772559,"eighty":2.349565,"marketCap":4962339},{"date":"2023-10-13","current":-1.032592,"twenty":-13.600564,"median":-7.692175,"eighty":2.349565,"marketCap":4714222},{"date":"2023-10-20","current":-0.889932,"twenty":-13.59794,"median":-7.548901,"eighty":2.349565,"marketCap":4062915},{"date":"2023-10-27","current":-0.910312,"twenty":-13.594777,"median":-7.495615,"eighty":2.380579,"marketCap":4155959},{"date":"2023-11-03","current":-1.032592,"twenty":-13.594777,"median":-7.408317,"eighty":2.380579,"marketCap":4714222},{"date":"2023-11-10","current":-1.019006,"twenty":-13.177141,"median":-7.342171,"eighty":2.380579,"marketCap":4652193},{"date":"2023-11-17","current":-1.0893,"twenty":-13.177141,"median":-7.269972,"eighty":2.380579,"marketCap":4621178},{"date":"2023-11-24","current":-1.235413,"twenty":-12.975635,"median":-7.182382,"eighty":2.380579,"marketCap":5241041},{"date":"2023-12-01","current":-1.106873,"twenty":-12.629773,"median":-7.007202,"eighty":2.380579,"marketCap":4695731},{"date":"2023-12-08","current":-1.056743,"twenty":-12.418157,"median":-6.998719,"eighty":2.370241,"marketCap":4483060},{"date":"2023-12-15","current":-1.071168,"twenty":-12.212374,"median":-6.998719,"eighty":2.370241,"marketCap":4544256},{"date":"2023-12-22","current":-1.121156,"twenty":-11.979138,"median":-6.998719,"eighty":2.380579,"marketCap":4756321},{"date":"2023-12-29","current":-1.016895,"twenty":-11.920554,"median":-6.89238,"eighty":2.390917,"marketCap":4314013},{"date":"2024-01-05","current":-1.064026,"twenty":-11.920554,"median":-6.873859,"eighty":2.401255,"marketCap":4513960},{"date":"2024-01-12","current":-1.060456,"twenty":-11.655378,"median":-6.832022,"eighty":2.401255,"marketCap":4498813},{"date":"2024-01-19","current":-1.014039,"twenty":-11.628829,"median":-6.811682,"eighty":2.40197,"marketCap":4301895},{"date":"2024-01-26","current":-0.917708,"twenty":-11.610032,"median":-6.667485,"eighty":2.401255,"marketCap":3893229},{"date":"2024-02-02","current":-0.966981,"twenty":-11.610032,"median":-6.622506,"eighty":2.401255,"marketCap":4102262},{"date":"2024-02-09","current":-0.942345,"twenty":-11.610032,"median":-6.485165,"eighty":2.401255,"marketCap":3997746},{"date":"2024-02-16","current":-0.960822,"twenty":-11.543264,"median":-6.357923,"eighty":2.401255,"marketCap":4076133},{"date":"2024-02-23","current":-0.942345,"twenty":-11.336275,"median":-6.201374,"eighty":2.401255,"marketCap":3997746},{"date":"2024-03-01","current":-0.9793,"twenty":-11.331617,"median":-6.086726,"eighty":2.390917,"marketCap":4154520},{"date":"2024-03-08","current":-0.948504,"twenty":-11.316925,"median":-5.949361,"eighty":2.390917,"marketCap":4023875},{"date":"2024-03-15","current":-1.040891,"twenty":-11.316925,"median":-5.851013,"eighty":2.390917,"marketCap":4415811},{"date":"2024-03-22","current":-1.120959,"twenty":-11.316925,"median":-5.832266,"eighty":2.390917,"marketCap":4755488},{"date":"2024-03-28","current":-1.467659,"twenty":-11.316925,"median":-5.824122,"eighty":2.390917,"marketCap":5431340},{"date":"2024-04-05","current":-1.5153,"twenty":-11.299241,"median":-5.742402,"eighty":2.401255,"marketCap":5607646},{"date":"2024-04-12","current":-1.452291,"twenty":-11.299241,"median":-5.609265,"eighty":2.401255,"marketCap":5374468},{"date":"2024-04-19","current":-1.513763,"twenty":-11.299241,"median":-5.418654,"eighty":2.401255,"marketCap":5601958},{"date":"2024-04-26","current":-1.444684,"twenty":-11.298331,"median":-4.796223,"eighty":2.390917,"marketCap":5346316},{"date":"2024-05-03","current":-1.421554,"twenty":-11.294692,"median":-4.589716,"eighty":2.390917,"marketCap":5260722},{"date":"2024-05-10","current":-1.352398,"twenty":-11.137361,"median":-4.492615,"eighty":2.390917,"marketCap":5004795},{"date":"2024-05-17","current":-1.486679,"twenty":-11.007857,"median":-4.094418,"eighty":2.390917,"marketCap":5346031},{"date":"2024-05-24","current":-1.573666,"twenty":-11.007857,"median":-3.431171,"eighty":2.390917,"marketCap":5658831},{"date":"2024-05-31","current":-1.581574,"twenty":-11.007857,"median":-3.393517,"eighty":2.390917,"marketCap":5687268},{"date":"2024-06-07","current":-0.919921,"twenty":-11.007857,"median":-3.341743,"eighty":2.390917,"marketCap":3307995},{"date":"2024-06-14","current":-1.240562,"twenty":-11.007857,"median":-3.294676,"eighty":2.401255,"marketCap":4461005},{"date":"2024-06-21","current":-1.013211,"twenty":-11.007857,"median":-3.162889,"eighty":2.40197,"marketCap":3643461},{"date":"2024-06-28","current":-0.994603,"twenty":-11.007857,"median":-3.040516,"eighty":2.404114,"marketCap":3576546},{"date":"2024-07-05","current":-0.979121,"twenty":-11.007857,"median":-2.880488,"eighty":2.404114,"marketCap":3520875},{"date":"2024-07-12","current":-1.004753,"twenty":-11.007857,"median":-2.720461,"eighty":2.404114,"marketCap":3613045},{"date":"2024-07-15","current":-1.03551,"twenty":-11.007857,"median":-2.701635,"eighty":2.404114,"marketCap":3723648},{"date":"2024-08-02","current":-2.46286,"twenty":-10.719359,"median":-2.605383,"eighty":2.485523,"marketCap":8856333},{"date":"2024-08-09","current":-1.534647,"twenty":-10.586968,"median":-2.551021,"eighty":2.485523,"marketCap":5518519},{"date":"2024-08-16","current":-1.735203,"twenty":-10.362651,"median":-2.475667,"eighty":2.485523,"marketCap":6098860},{"date":"2024-08-23","current":-1.786238,"twenty":-10.362651,"median":-2.45218,"eighty":2.485523,"marketCap":6278238},{"date":"2024-08-30","current":-1.531061,"twenty":-10.362651,"median":-2.411138,"eighty":2.485523,"marketCap":5381347},{"date":"2024-09-06","current":-1.531061,"twenty":-10.207138,"median":-2.361577,"eighty":2.485523,"marketCap":5381347},{"date":"2024-09-13","current":-1.377955,"twenty":-10.104326,"median":-2.230966,"eighty":2.485523,"marketCap":4843212},{"date":"2024-09-20","current":-1.352438,"twenty":-10.066151,"median":-2.149851,"eighty":2.485523,"marketCap":4753523},{"date":"2024-09-27","current":-1.352438,"twenty":-9.745323,"median":-2.089766,"eighty":2.485523,"marketCap":4753523},{"date":"2024-10-04","current":-1.301402,"twenty":-9.664984,"median":-1.937601,"eighty":2.485523,"marketCap":4574145},{"date":"2024-10-11","current":-1.301402,"twenty":-9.53737,"median":-1.901283,"eighty":2.485523,"marketCap":4574145},{"date":"2024-10-18","current":-1.531061,"twenty":-9.53737,"median":-1.842296,"eighty":2.485523,"marketCap":5381347},{"date":"2024-10-25","current":-1.45285,"twenty":-9.392914,"median":-1.815076,"eighty":2.485523,"marketCap":5106450},{"date":"2024-10-31","current":-1.441749,"twenty":-9.256878,"median":-1.798474,"eighty":2.485523,"marketCap":5067435},{"date":"2024-11-08","current":-1.633132,"twenty":-9.1175,"median":-1.781386,"eighty":2.494763,"marketCap":5740103},{"date":"2024-11-15","current":-1.363079,"twenty":-9.1175,"median":-1.761823,"eighty":2.494763,"marketCap":5157124},{"date":"2024-11-22","current":-1.078611,"twenty":-9.074418,"median":-1.741472,"eighty":2.494763,"marketCap":4080854},{"date":"2024-11-29","current":-1.185287,"twenty":-9.074418,"median":-1.737578,"eighty":2.494763,"marketCap":4484456},{"date":"2024-12-06","current":-1.102317,"twenty":-9.074418,"median":-1.72535,"eighty":2.494763,"marketCap":4170544},{"date":"2024-12-13","current":-1.092834,"twenty":-9.074418,"median":-1.697169,"eighty":2.494763,"marketCap":4134668},{"date":"2024-12-20","current":-0.989596,"twenty":-9.074418,"median":-1.683161,"eighty":2.494763,"marketCap":3744072},{"date":"2024-12-27","current":-1.127444,"twenty":-9.074418,"median":-1.665338,"eighty":2.494763,"marketCap":4265614},{"date":"2025-01-03","current":-1.126022,"twenty":-9.074418,"median":-1.650335,"eighty":2.494763,"marketCap":4260233},{"date":"2025-01-10","current":-2.02684,"twenty":-9.074418,"median":-1.643238,"eighty":2.504003,"marketCap":7668419},{"date":"2025-01-17","current":-2.346867,"twenty":-9.074418,"median":-1.643238,"eighty":2.504003,"marketCap":8879222},{"date":"2025-01-24","current":-2.323162,"twenty":-9.074418,"median":-1.643238,"eighty":2.504003,"marketCap":8789533},{"date":"2025-01-31","current":-2.169074,"twenty":-9.074418,"median":-1.643238,"eighty":2.504003,"marketCap":8206554},{"date":"2025-02-07","current":-1.967576,"twenty":-9.074418,"median":-1.643238,"eighty":2.504003,"marketCap":7444196},{"date":"2025-02-14","current":-1.789783,"twenty":-9.074418,"median":-1.643238,"eighty":2.504003,"marketCap":6771528},{"date":"2025-02-21","current":-1.766077,"twenty":-9.074418,"median":-1.643238,"eighty":2.504003,"marketCap":6681839},{"date":"2025-02-28","current":-1.635695,"twenty":-9.074418,"median":-1.634232,"eighty":2.504003,"marketCap":6188549},{"date":"2025-03-07","current":-1.552725,"twenty":-8.780536,"median":-1.620329,"eighty":2.513243,"marketCap":5874637},{"date":"2025-03-14","current":-1.564578,"twenty":-8.412491,"median":-1.608904,"eighty":2.513243,"marketCap":5919481},{"date":"2025-03-21","current":-1.623842,"twenty":-8.140487,"median":-1.608904,"eighty":2.513243,"marketCap":6143704},{"date":"2025-03-28","current":-1.564578,"twenty":-8.140487,"median":-1.606063,"eighty":2.513243,"marketCap":5919481},{"date":"2025-04-04","current":-1.128035,"twenty":-8.140487,"median":-1.600137,"eighty":2.513243,"marketCap":4955323},{"date":"2025-04-11","current":-1.06168,"twenty":-8.138805,"median":-1.588883,"eighty":2.504003,"marketCap":4663834},{"date":"2025-04-17","current":-1.051472,"twenty":-8.138805,"median":-1.582871,"eighty":2.504003,"marketCap":4618989},{"date":"2025-04-25","current":-1.163765,"twenty":-8.140487,"median":-1.575319,"eighty":2.513243,"marketCap":5112279},{"date":"2025-05-02","current":-0.79626,"twenty":-8.128354,"median":-1.569338,"eighty":2.513243,"marketCap":3497875},{"date":"2025-05-09","current":-0.831888,"twenty":-7.906284,"median":-1.567818,"eighty":2.513243,"marketCap":3654383},{"date":"2025-05-16","current":-0.504357,"twenty":-7.789967,"median":-1.560316,"eighty":2.513243,"marketCap":2331468},{"date":"2025-05-23","current":-0.666884,"twenty":-7.667608,"median":-1.552725,"eighty":2.513243,"marketCap":3082772},{"date":"2025-05-30","current":-0.73627,"twenty":-7.530024,"median":-1.545313,"eighty":2.513243,"marketCap":3403519},{"date":"2025-06-06","current":-0.997909,"twenty":-7.471414,"median":-1.537812,"eighty":2.513243,"marketCap":4612986},{"date":"2025-06-13","current":-0.951288,"twenty":-7.408317,"median":-1.531061,"eighty":2.513243,"marketCap":4397473},{"date":"2025-06-20","current":-0.92369,"twenty":-7.30067,"median":-1.53031,"eighty":2.520635,"marketCap":4269895},{"date":"2025-06-27","current":-0.9845,"twenty":-7.249446,"median":-1.528821,"eighty":2.520635,"marketCap":4550999},{"date":"2025-07-03","current":-0.959864,"twenty":-7.059068,"median":-1.518307,"eighty":2.520635,"marketCap":4437116},{"date":"2025-07-11","current":-0.979978,"twenty":-6.992487,"median":-1.514531,"eighty":2.520635,"marketCap":4530097},{"date":"2025-07-18","current":-0.985436,"twenty":-6.874917,"median":-1.505812,"eighty":2.520635,"marketCap":4555324},{"date":"2025-07-23","current":-0.985436,"twenty":-6.86005,"median":-1.502713,"eighty":2.520635,"marketCap":4555324}],"updateTime":1753374079092}}}